ALSPW Spineway SAS

Partnership with Key Opinion Leaders and successful trainings

Partnership with Key Opinion Leaders and successful trainings

Press release        Ecully, May 30, 2024 – 6 p.m.



SPINEWAY organizes surgical training sessions

in the use of ESP and KAPHORN implants

The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it trained nearly 30 spine surgeons in the use of its product lines during a series of sessions held in April and May.

These surgeons from several countries (Thailand, Indonesia, Vietnam, Tunisia, Switzerland and France) were trained in the placement of its ESP disc prostheses (lumbar, cervical) and the Kaphorn posterior fixation system.

The courses were conducted by experienced French surgeons who use Spineway products, either in the operating room or at a symposium. They facilitated the exchange of knowledge and skills to promote clinical excellence and the adoption of Spineway products. An interactive, hands-on approach allowed participants to discover the Group’s products or deepen their expertise, benefiting from personalized support and live demonstrations.

Training in operating room in France

On April 15, Professor Jean-Yves Lazennec (AP-HP Hôpital La Pitié-Salpêtrière, Paris) invited Doctor Alessandro Rustia (Switzerland), who witnessed several procedures using ESP prostheses.

On April 19, Pr. Luthfi Gatam, (Jakarta, Indonesia), witnessed a total lumbar disc replacement with the Group’s LP-ESP prosthesis, performed by Dr. Marie-Charlotte Têtard (CHU Saint-Etienne).

On May 3, Pr (CHU La Timone, Marseille) visited Dr (Clinique des Cèdres, Toulouse) to share his surgical approach to total lumbar disc replacement.



On May 13 and 14, Dr. Pascal Sabatier (Clinique des Cèdres, Toulouse) welcomed three Tunisian orthopedic surgeons to the operating room as part of Spineway’s international training program. The surgeons received two days of operating room training on the KAPHORN posterior side-loading osteosynthesis system. They attended several surgical procedures, including cases of degenerative pathologies, deformities and revisions.

Symposium in Bangkok attended by around 20 surgeons

On May 16, Spineway organized a symposium dedicated to degenerative spine pathologies, and cervical and lumbar prostheses (CP-ESP and LP-ESP) on the sidelines of the Global Spine Congress Bangkok 2024.

The event saw Pr. (AP-HP Hôpital Bichat-Beaujon, Paris), a user of Spineway products, share his expertise in ESP technologies with around 20 surgeons from Thailand, Indonesia and Vietnam. They discussed prosthesis design and indications, as well as significant clinical cases and outcomes.



Through these training courses, which will continue throughout June, and in line with its development strategy, Spineway is strengthening its reputation and partnerships with key opinion leaders (KOLs) in spine surgery. The Group plans to continue its commercial rollout and confirms its aim of becoming a major player in less invasive spine treatments.

Next event:

July 17, 2024 – H1 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of independent distributors and derives more than 70% of its revenue from exports.

ISIN: FR001400BVK2 – ALSPW        

Contacts:

SPINEWAY GROUP



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060
Eligible PEA / PME



ALSPW





Euronext Growth

  

AELIUM



Finance & Communication





Investor relations



Solène Kennis





Attachment



EN
30/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

Spineway : 2025 annual results

Spineway : 2025 annual results Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY2025 annual results Revenue up 4%Improved resultsStronger growth potential Condensed consolidated income statement20252024Pro forma* 2024ReportedIn thousands of euros Revenue12,43011,950 11,950Cost of sales-3,783-3,699 -3,699Gross margin 8,6478,250 8,250% of revenue69,6%69,0% 69%Net operating expenses-10,780-10,227 -9,131Of which external expenses-3,967-3,522 -3,646Of which personnel expenses-4,600-4,890 -4,890     Of which other op. income and expenses-1,436-920 -358Of which dep., amort., and provisions-777-895 ...

 PRESS RELEASE

SPINEWAY : Résultats annuels 2025

SPINEWAY : Résultats annuels 2025 Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4%Une amélioration des résultatsUn potentiel de croissance renforcé Compte de résultat consolidé résumé20252024Proforma* 2024PubliéEn milliers d'euros Chiffre d'affaires12 43011 950 11 950Coût des ventes-3 783-3 699 -3 699Marge brute8 6478 250 8 250% du CA69,6%69,0% 69%Coûts nets d’exploitation-10 780-10 227 -9 131Dont charges externes-3 967-3 522 -3 646Dont charges de personnel-4 600-4 890 -4 890     Dont autres pdts et ch. d'exploitation-1 43...

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch